# Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

> **NCT05088057** · PHASE2 · UNKNOWN · sponsor: **Aiping Shi** · enrollment: 30 (estimated)

## Conditions studied

- Triple Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05088057
- **Lead sponsor:** Aiping Shi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-20
- **Primary completion:** 2024-08-19
- **Final completion:** 2024-11-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05088057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05088057, "Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05088057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*